LAMA2 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Each patient underwent a comprehensive clinical workup and were grouped as those with suspected dystroglycanopathy (Group I) or suspected merosin-deficient CMD (Group II).